Stock Analysis, Dividends, Split History

BTX / BioTime, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)261.36
Enterprise Value ($M)234.02
Book Value ($M)100.98
Book Value / Share0.80
Price / Book2.91
NCAV ($M)27.00
NCAV / Share0.21
Price / NCAV10.90
Share Statistics
Common Stock Shares Outstanding 126,866,000
Common Shares Outstanding 126,869,152
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.14
Return on Assets (ROA)-0.16
Return on Equity (ROE)-0.20
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio5.90
Income Statement (mra) ($M)
Revenue From Grants1,666,000.00
Royalty Revenue389,000.00
Subscription And Advertisement Revenues1,395,000.00
Sales Revenue Goods Net8,000.00
Revenue Grants0.00
Sales Revenue Net3,458,000.00
Operating Income-38.90
Net Income-23.29
Earnings Per Share Basic-0.17
Earnings Per Share Diluted-0.17
Cash Flow Statement (mra) ($M)
Cash From Operations-30.52
Cash from Investing-10.22
Cash from Financing-10.22
Identifiers and Descriptors
Central Index Key (CIK)876343
Related CUSIPS
09066L955 09066L905

Split History

Stock splits are used by BioTime, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Can The Uptrend Continue for BioTime (BTX)?

2018-09-04 zacks
Investors certainly have to be happy with BioTime, Inc. (BTX - Free Report) and its short term performance. After all, the stock has jumped by 13.5% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for BTX? (10-0)

BioTime, Inc. (BTX) CEO Aditya Mohanty on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Good day, ladies and gentlemen, and welcome to the BioTime's Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. And as a reminder, today's conference is being recorded. I would now like to turn the call over to Mr. David Nakasone. Sir, you may begin. (0-1)

BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates

2018-08-02 zacks
BioTime (BTX - Free Report) just came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.

BioTime (BTX) in Focus: Stock Moves 7.3% Higher

2018-07-12 zacks
BioTime, Inc. (BTX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.03 –$2.38 in the past one-month time frame, witnessed a sharp increase yesterday. (0-1)

Asterias Biotherapeutics: A Game Changer For Cervical Spinal Cord Injuries And Cancer

2018-06-22 seekingalpha
Asterias Biotherapeutics is a micro-cap biotechnology company that is focused on cell-based therapies for spinal cord injuries and broad cancer. (73-3)

Sangamo Therapeutics: Investability Outlook

2018-06-13 seekingalpha
Like BioTime (BTX), which we discussed recently, Sangamo (SGMO) is another company that began the wrong way, with a platform, and then, and only recently, moved on to therapeutics. But, oh boy, what a move it has been! The company changed its name from Sangamo Biosciences to Sangamo Therapeutics to emphasize that change in direction after its new CEO Sandy Macrae took over, and within about 24 months, changed from a sleepy lab-oriented laggard to a company with multiple deals and pipeline assets. (68-6)

Your Daily Pharma Scoop: Secondaries Review June 4-11

2018-06-12 seekingalpha
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis. (169-14)

BioTime's (BTX) CEO Adi Mohanty on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the BioTime's First Quarter Results Conference Call. As a reminder, this conference call is being recorded. (7-4)

BioTime (BTX): Moving Average Crossover Alert

2018-04-10 zacks
BioTime, Inc. (BTX - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for BTX broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. (10-0)

BioTime, Inc.: An Undervalued Regenerative Medicine Company

2018-04-09 seekingalpha
If approved, it would be the first therapy for dry AMD, which could be a $22 billion market in the United States. (64-5)

CUSIP: 09066L105